
    
      This study will utilize a randomized, placebo-controlled, double-blinded design. Patients
      admitted with confirmed COVID-19, and at least 1 of the following: requiring oxygen
      supplementation (â‰¤4 liters of oxygen via nasal cannula or increase from baseline), bilateral
      infiltrates on CT/CXR, age >65, diabetes, hypertension, BMI > 35, chronic lung disease,
      cardiovascular disease, chronic kidney disease, cancer (hematologic malignancies, lung
      cancer, and metastatic disease), will be randomized in a 1:1 fashion to hydroxychloroquine
      400 mg PO BID x 2 doses, then 200 mg PO BID x 8 doses or placebo at a matching schedule.
    
  